SILVER SPRING, Md. and VIENNA, Austria, Feb. 15, 2013 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), an international biotechnology and clinical stage provider of natural products and cell and gene therapy solutions for the treatment of diseases, announced today its subsidiary, Austrianova Singapore Pte. Ltd. (ASPL) has reported the successful establishment of a research "cell bank" that will ultimately be used to obtain the numbers of cells necessary for conducting the Company's late-phase clinical trials in patients with advanced, inoperable, pancreatic cancer. The research cell bank was established by ViruSure GmbH, an Austrian Contract Research Organization located in Vienna, Austria. The genetically augmented human cells in the cell bank are the same as those used in the two successfully completed mid-phase clinical trials in advanced non-resectable pancreatic cancer patients previously reported by Nuvilex. ViruSure is an important international biosafety company in the biotechnology community with substantial expertise in cell culture, virus, prion, and other infectious agent testing, as well as cell growth and assessment capabilities. ViruSure assessed the purity and sterility of our cells. Before the cell bank was established, the cells were tested and shown to be free of contamination by mycoplasma, a type of bacteria that can be toxic to humans. The validation that the cells in the cell bank are "mycoplasma-free" is a prerequisite for further expansion of the cell line required for Nuvilex's late-phase clinical studies in advanced pancreatic cancer that are currently in preparation. Nuvilex is proud to announce that completion of this stage successfully showed the cells were mycoplasma-free. Since that initial assessment, ViruSure has been carrying out the amplification of these same cells on a "fast track" basis. These cells will ultimately be used for encapsulation and subsequently implanted in patients for the treatment of advanced, inoperable pancreatic cancer. "We are excited that the initial steps required for the commencement of additional clinical trials of our encapsulated cell therapy in advanced pancreatic cancer have been made possible through the establishment of this cell bank," said Dr. Brian Salmons, CEO of ASPL.